GNPX

Genprex, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website genprex.com
Employees(FY) 31
ISIN US3724462037

Performance

-47.37%

+166.34%

+71.87%

-56.86%

-88.04%

YTD

-89.4%

Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Advanced Technical Analysis

Technical Analysis of GNPX 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 46 suggesting a neutral stance, and a Technical Score of 28 reinforcing the bearish outlook. This combination points to a challenging environment for the stock, with potential weakness in price ...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of GNPX

Stock Rank

Recent News & Updates

2024-11-19 20:29
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer(Prnewswire)
2024-11-04 20:29
Genprex Collaborators Present Positive Preclinical Data on Reqorsa Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting(Prnewswire)
2024-10-30 21:29
Genprex to Participate in 2024 BIO Europe Conference(Prnewswire)
2024-10-27 21:29
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma(Prnewswire)
2024-10-23 21:29
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive(Prnewswire)
2024-10-15 19:45
Genprex advances to highest dose in Phase I Acclaim-3 trial of Reqorsa(Yahoo Finance)
2024-10-14 21:29
Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer(Prnewswire)
2024-10-09 21:29
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics(Prnewswire)
2024-10-06 21:29
Genprex Collaborators to Present Positive Preclinical Data on Reqorsa Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting(Prnewswire)
2024-09-22 21:29
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes(Prnewswire)
2024-09-18 21:29
Genprex Announces Formation of Mesothelioma Clinical Advisory Board(Prnewswire)
2024-09-08 21:29
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics(Prnewswire)
2024-09-03 21:29
Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes(Prnewswire)
2024-09-02 20:15
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences(Prnewswire)
2024-08-14 21:30
Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials(Prnewswire)
2024-08-13 21:25
Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer(Prnewswire)
2024-08-12 20:31
Genprex Granted Patent in Singapore for Reqorsa Gene Therapy with PD-1 Antibodies to Treat Cancers(Prnewswire)
2024-08-07 20:30
Genprex to Present at the August Sidoti Microcap Conference(Prnewswire)
2024-06-26 20:31
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update(Prnewswire)
2024-05-29 20:31
Genprex to Present at the 2024 BIO International Convention(Prnewswire)
2024-05-20 00:53
GNPX Stock Earnings: Genprex Beats EPS for Q1 2024(Investorplace)
2024-05-14 16:42
Genprex dosing subjects in trial of combination therapy for small-cell lung cancer(Yahoo Finance)
2024-05-13 20:31
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer(Prnewswire)
2024-05-12 20:31
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors(Prnewswire)
2024-05-08 06:08
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner(Prnewswire)
2024-05-06 21:15
Sidoti Events, LLC's Virtual May Micro-Cap Conference(Accesswire)
2024-04-30 20:31
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences(Prnewswire)
2024-04-08 20:31
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting(Prnewswire)
2024-04-03 20:57
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up(Yahoo Finance)
2024-04-03 20:57
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up(Zacks)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.